Drug Profile
REX 003
Alternative Names: REX-003Latest Information Update: 19 Feb 2022
Price :
$50
*
At a glance
- Originator Rexgenero
- Developer Ixaka
- Class Stem cell therapies
- Mechanism of Action Cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Peripheral ischaemia
Most Recent Events
- 19 Feb 2022 Discontinued - Phase-I/II for Peripheral ischaemia (Parenteral) (Ixaka pipeline, February 2022)
- 18 Jan 2021 Rexgenero is now called Ixaka
- 09 Aug 2016 Phase-I/II clinical trials in Peripheral ischaemia (Parenteral) before August 2016